• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

视网膜厚度偏差:一种评估糖尿病性黄斑水肿的新型光学相干断层扫描参数。

Retinal Thickness Deviation: A New OCT Parameter for Assessing Diabetic Macular Edema.

作者信息

Marolo Paola, Borrelli Enrico, Gelormini Francesco, Boscia Giacomo, Parisi Guglielmo, Fallico Matteo, Barresi Costanza, Lari Giorgio, Berni Alessandro, Bandello Francesco, Reibaldi Michele

机构信息

Department of Ophthalmology, University of Turin, 10126 Turin, Italy.

Ophthalmology Department, Vita-Salute San Raffaele University, 20132 Milan, Italy.

出版信息

J Clin Med. 2023 Jun 11;12(12):3976. doi: 10.3390/jcm12123976.

DOI:10.3390/jcm12123976
PMID:37373669
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10299100/
Abstract

(1) Purpose: To determine the "retinal thickness deviation" (RTD) in diabetic macular edema (DME) eyes treated with intravitreal therapy and to establish associations between RTD and best-corrected visual acuity (BCVA). (2) Methods: We conducted a retrospective study, including consecutive patients with DME eyes undergoing intravitreal therapy with two years of follow-up. BCVA and central subfield thickness (CST) were collected at baseline and at 12 months and 24 months of follow-up. RTD was calculated as the absolute difference between measured and normative CST values at each time point. Linear regression analyses were performed between RTD and BCVA and between CST and BCVA. (3) Results: One hundred and four eyes were included in the analysis. The RTD was 177.0 (117.2) μm at baseline, 97.0 (99.7) μm at 12 months and 89.9 (75.3) μm at 24 months of follow-up ( < 0.001). RTD showed a moderate association with BCVA at baseline (R = 0.134, < 0.001) and 12 months (R = 0.197, < 0.001) and a substantial association at 24 months (R = 0.272, < 0.001). The CST showed a moderate association with BCVA at baseline (R = 0.132, < 0.001) and 12 months (R = 0.136, < 0.001), while the association was weak at 24 months (R = 0.065, = 0.009). (4) Conclusions: RTD showed a good association with visual outcome in patients with DME eyes undergoing intravitreal treatment.

摘要

(1) 目的:确定接受玻璃体腔内治疗的糖尿病性黄斑水肿(DME)眼的“视网膜厚度偏差”(RTD),并建立RTD与最佳矫正视力(BCVA)之间的关联。(2) 方法:我们进行了一项回顾性研究,纳入连续接受玻璃体腔内治疗且随访两年的DME眼患者。在基线、随访12个月和24个月时收集BCVA和中心子野厚度(CST)。RTD计算为每个时间点测量的CST值与正常CST值之间的绝对差值。对RTD与BCVA之间以及CST与BCVA之间进行线性回归分析。(3) 结果:104只眼纳入分析。随访基线时RTD为177.0(117.2)μm,12个月时为97.0(99.7)μm,24个月时为89.9(75.3)μm(<0.001)。RTD在基线时与BCVA呈中度关联(R = 0.134,<0.001),12个月时呈中度关联(R = 0.197,<0.001),24个月时呈显著关联(R = 0.272,<0.001)。CST在基线时与BCVA呈中度关联(R = 0.132,<0.001),12个月时呈中度关联(R = 0.136,<0.001),而在24个月时关联较弱(R = 0.065,= 0.009)。(4) 结论:RTD与接受玻璃体腔内治疗的DME眼患者的视力预后显示出良好的关联。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca6d/10299100/ecd0b095b788/jcm-12-03976-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca6d/10299100/f71c208fa12c/jcm-12-03976-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca6d/10299100/f53551906cc8/jcm-12-03976-g002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca6d/10299100/ecd0b095b788/jcm-12-03976-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca6d/10299100/f71c208fa12c/jcm-12-03976-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca6d/10299100/f53551906cc8/jcm-12-03976-g002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca6d/10299100/ecd0b095b788/jcm-12-03976-g003.jpg

相似文献

1
Retinal Thickness Deviation: A New OCT Parameter for Assessing Diabetic Macular Edema.视网膜厚度偏差:一种评估糖尿病性黄斑水肿的新型光学相干断层扫描参数。
J Clin Med. 2023 Jun 11;12(12):3976. doi: 10.3390/jcm12123976.
2
Visual Acuity in Retinal Vein Occlusion, Diabetic, and Uveitic Macular Edema: Central Subfield Thickness and Ellipsoid Zone Analysis.视网膜静脉阻塞、糖尿病性和葡萄膜炎性黄斑水肿的视力:中心凹下视网膜厚度和椭圆体带分析。
Ophthalmol Retina. 2021 Jul;5(7):633-647. doi: 10.1016/j.oret.2020.10.016. Epub 2020 Oct 29.
3
Bevacizumab versus triamcinolone for persistent diabetic macular edema: a randomized clinical trial.贝伐单抗与曲安奈德治疗持续性糖尿病黄斑水肿的随机临床试验。
Graefes Arch Clin Exp Ophthalmol. 2020 Mar;258(3):479-490. doi: 10.1007/s00417-019-04564-z. Epub 2019 Dec 23.
4
[Correlation of retinal sensitivity, visual acuity and central macular thickness in different types of diabetic macular edema].[不同类型糖尿病性黄斑水肿中视网膜敏感度、视力与黄斑中心厚度的相关性]
Zhonghua Yan Ke Za Zhi. 2013 Dec;49(12):1081-8.
5
Response of Diabetic Macular Edema to Anti-VEGF Medications Correlates with Improvement in Macular Vessel Architecture Measured with OCT Angiography.糖尿病性黄斑水肿对抗血管内皮生长因子药物的反应与光学相干断层扫描血管造影测量的黄斑血管结构改善相关。
Ophthalmol Sci. 2024 Jan 26;4(4):100478. doi: 10.1016/j.xops.2024.100478. eCollection 2024 Jul-Aug.
6
Atrophy of the central neuroretina in patients treated for diabetic macular edema.糖尿病性黄斑水肿患者的中枢性神经视网膜萎缩。
Acta Ophthalmol. 2019 Dec;97(8):e1054-e1061. doi: 10.1111/aos.14173. Epub 2019 Jun 22.
7
Predictive effect of TCED-HFV grading and imaging biomarkers on anti-VEGF therapy in diabetic macular edema.TCED-HFV 分级和影像学生物标志物对糖尿病黄斑水肿抗 VEGF 治疗的预测作用。
BMC Ophthalmol. 2023 May 23;23(1):232. doi: 10.1186/s12886-023-02973-7.
8
Prospective study of morphologic and functional parameter changes post intravitreal therapy for macular edema.玻璃体内注射治疗黄斑水肿后形态学和功能参数变化的前瞻性研究。
Graefes Arch Clin Exp Ophthalmol. 2020 Sep;258(9):1941-1947. doi: 10.1007/s00417-020-04715-7. Epub 2020 May 2.
9
Comparison of clinical outcomes of different components of diabetic macular edema on optical coherence tomography.比较光学相干断层扫描对不同糖尿病性黄斑水肿成分的临床疗效。
Graefes Arch Clin Exp Ophthalmol. 2019 Dec;257(12):2613-2621. doi: 10.1007/s00417-019-04471-3. Epub 2019 Sep 16.
10
Fundus autofluorescence in the evaluation of diabetic macular edema treatment response.眼底自发荧光在评估糖尿病黄斑水肿治疗反应中的应用。
Gac Med Mex. 2021;157(4):397-403. doi: 10.24875/GMM.M21000581.

引用本文的文献

1
Effect of simultaneous intravitreal ranibizumab and extended-release dexamethasone injection on patients with naïve versus refractory retinal vein occlusion macular edema: a prospective, multicenter, and interventional open-label study.玻璃体内注射雷珠单抗与长效地塞米松联合应用对初治与难治性视网膜静脉阻塞性黄斑水肿患者的疗效:一项前瞻性、多中心、开放标签干预性研究。
Int J Ophthalmol. 2025 May 18;18(5):860-867. doi: 10.18240/ijo.2025.05.11. eCollection 2025.
2
Structural and Vascular Features of Macula Related to the Recurrence of Macular Edema in Central Retinal Vein Occlusion After Anti-VEGF Therapy.与抗VEGF治疗后视网膜中央静脉阻塞黄斑水肿复发相关的黄斑结构和血管特征
J Ophthalmol. 2025 Feb 28;2025:8824342. doi: 10.1155/joph/8824342. eCollection 2025.
3

本文引用的文献

1
Comparing Objective Perimetry, Matrix Perimetry, and Regional Retinal Thickness in Mild Diabetic Macular Edema.比较客观视野计、矩阵视野计和轻度糖尿病性黄斑水肿的局部视网膜厚度。
Transl Vis Sci Technol. 2021 Nov 1;10(13):32. doi: 10.1167/tvst.10.13.32.
2
Long-Term Visual Outcomes and Morphologic Biomarkers of Vision Loss in Eyes With Diabetic Macular Edema Treated With Anti-VEGF Therapy.抗血管内皮生长因子治疗糖尿病黄斑水肿导致视力丧失眼的长期视觉结果和形态生物标志物。
Am J Ophthalmol. 2022 Mar;235:80-89. doi: 10.1016/j.ajo.2021.09.002. Epub 2021 Sep 10.
3
Association of Macular Thickness With Age and Age-Related Macular Degeneration in the Carotenoids in Age-Related Eye Disease Study 2 (CAREDS2), An Ancillary Study of the Women's Health Initiative.
Determining the Superiority of Vitrectomy vs Aflibercept for Treating Dense Diabetic Vitreous Hemorrhage: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.确定玻璃体切除术与阿柏西普治疗致密糖尿病性玻璃体出血的优势:一项随机临床试验的系统评价和荟萃分析
Clin Ophthalmol. 2023 Aug 15;17:2359-2370. doi: 10.2147/OPTH.S419478. eCollection 2023.
在妇女健康倡议的辅助研究——年龄相关性眼病研究 2(CAREDS2)中,黄斑厚度与年龄和年龄相关性黄斑变性的关系。
Transl Vis Sci Technol. 2021 Feb 5;10(2):39. doi: 10.1167/tvst.10.2.39.
4
Changes in inner retinal layer thickness in patients with exudative age-related macular degeneration during treatment with anti-vascular endothelial growth factor.抗血管内皮生长因子治疗渗出性年龄相关性黄斑变性患者期间视网膜内层厚度的变化
Medicine (Baltimore). 2020 Apr;99(17):e19955. doi: 10.1097/MD.0000000000019955.
5
Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial.随机接受阿柏西普、贝伐单抗或雷珠单抗治疗的糖尿病性黄斑水肿患者在治疗期间视力变化与中心子野厚度变化之间的关联:Protocol T随机临床试验的事后分析
JAMA Ophthalmol. 2019 Sep 1;137(9):977-985. doi: 10.1001/jamaophthalmol.2019.1963.
6
Correlation of Central Retinal Thickness and Visual Acuity in Diabetic Macular Edema.糖尿病性黄斑水肿中视网膜中央厚度与视力的相关性
JAMA Ophthalmol. 2018 Nov 1;136(11):1215-1216. doi: 10.1001/jamaophthalmol.2018.3848.
7
Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.持续给予瑞巴派特与添加地塞米松治疗持续性糖尿病黄斑水肿患者的效果:DRCR 网络的一项 2 期随机临床试验。
JAMA Ophthalmol. 2018 Jan 1;136(1):29-38. doi: 10.1001/jamaophthalmol.2017.4914.
8
Short-term vision gains at 12 weeks correlate with long-term vision gains at 2 years: results from the BEVORDEX randomised clinical trial of bevacizumab versus dexamethasone implants for diabetic macular oedema.12 周时的短期视力增益与 2 年时的长期视力增益相关:来自 BEVORDEX 贝伐单抗与地塞米松植入物治疗糖尿病黄斑水肿的随机临床试验的结果。
Br J Ophthalmol. 2018 Apr;102(4):479-482. doi: 10.1136/bjophthalmol-2017-310737. Epub 2017 Aug 4.
9
Postreceptor Neuronal Loss in Intermediate Age-related Macular Degeneration.中年相关性黄斑变性中的受体后神经元丢失
Am J Ophthalmol. 2017 Sep;181:1-11. doi: 10.1016/j.ajo.2017.06.005. Epub 2017 Jun 15.
10
Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema.雷珠单抗联合即时或延迟激光治疗与激光或曲安奈德联合延迟雷珠单抗治疗糖尿病性黄斑水肿的五年疗效
Am J Ophthalmol. 2016 Apr;164:57-68. doi: 10.1016/j.ajo.2015.12.025. Epub 2016 Jan 21.